Biogen Inc. (BIIB) has been upgraded to a 'Buy' rating as the company executes a strategic turnaround, with recent acquisitions and pipeline advancements offsetting erosion in its multiple sclerosis portfolio. The Q2 financial report highlighted a 3% year-over-year revenue growth, driven by contributions from Apellis,...
Biogen (BIIB) is set to report second-quarter 2026 earnings on July 29, with analysts expecting a beat based on recent performance where the company exceeded estimates by an average of 21.02% in the last quarter. Consensus estimates project sales of $2.47 billion and earnings of...
Biogen (BIIB) is exploring an acquisition of Raythera for up to $1 billion to bolster its immunology portfolio with preclinical anti-inflammatory assets. The deal structure includes milestones designed to mitigate upfront financial pressure, a move that has generated positive sentiment among observers and led to...
Pomerantz Law Firm is investigating potential securities fraud and unlawful business practices on behalf of investors of Biogen Inc. (NASDAQ: BIIB). The firm advises affected investors to contact their legal team regarding these claims, highlighting the firm's extensive history in corporate and securities litigation. The...
Biogen (BIIB) decided to advance its experimental Alzheimer's drug, BIIB080 (also known as diranersen), into late-stage testing despite recent trial data failing to meet its primary endpoint. Following the May 14, 2026 report of the Phase 2 "Celia" study results, Biogen highlighted "unprecedented and compelling"...
